

Advanced Medical Solutions Ltd

Premier Park, 33 Road One, Winsford Industrial Estate, Cheshire, CW7 3RT, United Kingdom 24th October 2024

Notified Body Confirmation Letter Reference: EU2023-607/755601

To whom it may concern,

Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation (EU) 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices

This letter confirms that, **BSI Group The Netherlands B.V.**, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number **2797** on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

Advanced Medical Solutions Ltd

Premier Park, 33 Road One, Winsford Industrial Estate, Cheshire, CW7 3RT, United Kingdom

SRN Number: GB-MF-000008822

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables below. Table 1 identifies the devices for which an MDR application has been received, written agreement concluded and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but the NB has <u>not</u> yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

BSI Group The Netherlands B.V. Say Building John M. Keynesplein 9, 1066 EP Amsterdam, The Netherlands





In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by the 20 Mar 2023 for the relevant devices.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by (EU) 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices
- 31 December 2027 for Class III devices and Class IIb implantable devices excluding Wellestablished technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)
- 31 December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- 31 December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of BSI Group The Netherlands B.V.,

Graeme Tunbridge

Senior Vice President, Medical Devices

BSI Group The Netherlands B.V. Say Building John M. Keynesplein 9, 1066 EP Amsterdam, The Netherlands





Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre- application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
Foam Lite Basic UDI-DI: 50327491810201KR	Class IIb excluding Class IIb implantable non-WET	N/A	MDD certificate# CE 01699 Expiry date: 26-May-2024 BSI NL NB# 2797
Silicone tri-laminate Foam; Tri-laminate Foam (non-adhesive); Bi-laminate Foam (adhesive); Bi-laminate Foam (non-adhesive, heel) Basic UDI-DI: 50327491810202KT	Class IIb excluding Class IIb implantable non-WET	N/A	MDD certificate# CE 01699 Expiry date: 26-May-2024 BSI NL NB# 2797
Silicone Wound Contact Layer Basic UDI-DI: 50327491810501L8	Class IIb excluding Class IIb implantable non-WET	N/A	MDD certificate# CE 01699 Expiry date: 26-May-2024 BSI NL NB# 2797
1-21A alginate; 1-2B alginate; 1-21DP reinforced alginate	Class IIb excluding Class IIb implantable non-WET	N/A	MDD certificate# CE 01699 Expiry date: 26-May-2024 BSI NL NB# 2797
Basic UDI-DI: 50327491810103KQ 41-2AP CMC/alginate; 14-2A CMC/alginate; 14-2AP CMC/alginate Basic UDI-DI: 50327491810101KL	Class IIb excluding Class IIb implantable non-WET	N/A	MDD certificate# CE 01699 Expiry date: 26-May-2024 BSI NL NB# 2797
Debridement Pad Basic UDI-DI: 50327491810801LP	Class IIb excluding Class IIb implantable non-WET	N/A	MDD certificate# 1434-MDD-267/2021 Expiry date: 27-May-2024 NB# 1434
Silver alginate I (Hydro-alginate antimicrobial wound dressing with Silver) Basic UDI-DI: 50327491810901LU	Class III	N/A	MDD certificate# CE 01699 Expiry date: 26-May-2024 MDD certificate# CE 70851 Expiry date: 26-May-2024 BSI NL NB# 2797
Silver alginate II (Silver alginate II antimicrobial wound dressing with silver sodium hydrogen zirconium phosphate) Basic UDI-DI: 50327491810902LW	Class III	N/A	MDD certificate# CE 01699 Expiry date: 26-May-2024 MDD certificate# CE 97750 Expiry date: 26-May-2024 BSI NL NB# 2797
Silver alginate IV (Silver alginate IV antimicrobial wound dressing with silver carbonate)	Class III	N/A	MDD certificate# CE 01699 Expiry date: 26-May-2024

BSI Group The Netherlands B.V. Say Building

John M. Keynesplein 9, 1066 EP Amsterdam, The Netherlands





Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre- application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
Basic UDI-DI: 50327491810903LY			MDD certificate# CE 608297 Expiry date: 26-May-2024 BSI NL NB# 2797
Silicone PHMB Foam wound dressings Basic UDI-DI: 50327491811002KQ	Class III	N/A	MDD certificate# 1434-MDD-431/2020 Expiry date: 27-May-2024 MDD certificate# 1434-MDD-430/2020 Expiry date: 27-May-2024 NB# 1434

Table 2: Devices covered by this letter and for which the NB is <u>NOT</u> responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
N/A	Choose an item.	N/A	N/A

Confirmation Letter Revision History

Date	Action
2024/01/03	Initial issue
2024/09/19	Addition of Class IIb device Debridement Pad to the letter in table 2.
2024/10/24	Transfer of devices Debridement Pad and Silicone PHMB Foam wound dressings from table 2 to table 1 to reflect BSI being responsible for appropriate surveillance.

BSI Group The Netherlands B.V. Say Building

John M. Keynesplein 9, 1066 EP Amsterdam, The Netherlands

